Mike lark, Phd, project leader
Dr. Lark, BioMotiv Project Leader, has over 30 years of experience at leading and managing drug discovery and development teams at both large pharmaceutical and small biotech companies.
Prior to joining BioMotiv, he was CSO and Sr. Vice President of Research at Trevena Inc., where he was a member of the executive team and was responsible for the drug discovery and non-clinical development functions within the company. Prior to Trevena, Dr. Lark was Vice President of Biology at Centocor R&D where he was responsible for the therapeutic discovery strategy and execution in immunology, oncology, tissue remodeling and biomarkers, and Director of Musculoskeletal Diseases at GlaxoSmithKline, where he managed a portfolio of drug discovery projects targeting osteoporosis, osteoarthritis, rheumatoid arthritis and psoriasis. Dr. Lark started his industry career as a Senior Investigator at Merck Research laboratories, where he led a drug discovery team targeting matrix metalloproteinase-3 for the treatment of osteoarthritis. He has published over 130 peer reviewed papers, reviews and book chapters and is a co-inventor on 11 patents.
Dr. Lark received his B.S. in Microbiology from the Pennsylvania State University and his Ph.D. in Molecular Biology and Microbiology from the Case Western Reserve University Medical School. He completed a postdoctoral fellowship in the Department of Pathology at The University of Washington.
Russell Wyborski, phd, Project Manager
Dr. Russell Wyborski has over 25 years of drug discovery and product development experience at Pfizer and Avon Products. His research experience includes work in the neuroscience, cardiovascular, inflammation, and skin biology therapeutic areas.
Dr. Wyborski received his Ph.D. in Biochemistry from Indiana University and completed a Postdoctoral Fellowship in Neurobiology at the Washington University at St. Louis Medical School.
Jeff Edelson, MD, Chief medical officer
Dr. Jeff Edelson has more than 30 years of drug development experience, having served in senior clinical R&D roles for several biotech and pharmaceutical firms including SmithKline Beecham, Therion Biologics, GlaxoSmithKline, Aventis and Johnson and Johnson Pharmaceutical Research and Development, where he was most recently the Therapeutic Area Head of Novel Therapeutics. He has experience developing immuno-oncology products, including cancer vaccines, as well as products for pulmonary, immunology, neurology, and therapeutic oncology across all phases of development.
Dr. Edelson earned his MD at the University of Toronto.
Teresa Byrne, Director of Clinical and Regulatory Operations
Teresa has more than 17 years of pharmaceutical industry experience, including clinical research experience across multiple therapeutic areas including cardiovascular, pulmonary, immunology, vaccines and oncology. Prior to joining BioMotiv, Teresa was the Director of Global Clinical Operations for a small CRO, and was responsible for all clinical trial management, project management and regional monitoring activities across the global organization. For many years, Teresa held roles in clinical trial management and clinical operations at companies such as GSK, Johnson & Johnson, and Novartis Vaccines.
Teresa has a BA degree in biology from Rutger’s University and has done post-graduate work in clinical pharmacology at Thomas Jefferson University.
Puneet Sodhi, PhD, Clinical and Regulatory Operations Director
Dr. Puneet Sodhi possesses a broad life science background with over 10 years of academic and drug discovery-based research experience in multiple therapeutic areas. While focused on neuroscience, her experience includes ophthalmology, neuropathic pain, and neurodegeneration. Prior to joining Biomotiv, Puneet was a Postdoctoral Scholar at AstraZeneca focused on identifying novel biomarkers for amyotrophic lateral sclerosis (ALS) to address aberrant signaling that occurs prior to motor neuron loss. In addition, she served as an advisor in the Rev1 Ventures Advisor Network to aid in the growth of Rev1 Ventures portfolio companies.
Puneet received her PhD in Neuroscience from Ohio State University. Her graduate work examined the neuromodulation of retinal ganglion cell photoreceptors to aid in development of non-invasive strategies for early detection in retinal disease states. Puneet graduated from the Honors Program at the University of Michigan with a BS in Neuroscience and in Psychology.
tony esposito, director of quality systems
Tony Esposito brings more than 25 years of pharmaceutical industry experience with him to this role. He provides compliance leadership, ensuring GXP compliance across all BioMotiv projects and subsidiaries. He is responsible for developing and prioritizing audit strategy, leading regulatory authority inspections, vendor assessment/oversight and provide guidance/interpretation on GXP regulations, standards and quality systems.
Tony has broad clinical research and quality experience, across multiple therapeutic areas including immunology (gastrointestinal, dermatology and rheumatoid arthritis), neuroscience, cardiovascular, pulmonary, endocrinology, ophthalmology, oncology, and stem cells. Prior to joining BioMotiv, Tony spent the majority of his career at Janssen (Johnson & Johnson) as a leader of clinical quality for the immunology/biologics division (Centocor) and was responsible for quality strategy, management, and leadership across the global organization. He has held various roles in quality and clinical operations at Janssen (Johnson & Johnson), Bristol Myers-Squibb, Pharma Net (CRO), NYU Medical Center/Bellevue Hospital and Memorial Sloan-Kettering Cancer Center.
Tony has degrees in Psychology and English from Rutgers University.
Franca Stedile Angeli, MD, PhD, Clinical Project Leader
Formerly at the Texas Heart Institute (UT), UCSF and Penn Med, Franca Stedile Angeli, MD, PhD, has a broad technical background of more than 15 years of experience in R&D, with specific training and expertise in designing, conducting and managing pre-clinical and clinical studies; data collection (including eCOA), statistical analysis, and database management; understanding and applying regulatory, ethical, and institutional policies and procedures; supporting IND/NDA fillings; and supervising work in single and multicentric clinical trials as well in laboratory settings.
Dr. Angeli holds a PhD in Clinical and Translational Research from the Pontificia Universidade Catolica do Rio Grande do Sul, Brazil, and a MD from the Universidade de Caxias do Sul, Brazil, as well as a BA in Business Administration from the Universidade Federal do Rio Grande do Sul, Brazil. She completed her post-doctoral fellowship at the University of Texas, Texas Heart Institute in Houston and a Cardiology Fellowship at the Pontificia Univeridade Catolica do Rio Grande do Sul, Brazil.